Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash & Equivalents (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cash & Equivalents for 10 consecutive years, with $184.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 256.28% to $184.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $184.8 million through Dec 2025, up 256.28% year-over-year, with the annual reading at $184.8 million for FY2025, 256.28% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $184.8 million at Akebia Therapeutics, up from $166.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $252.8 million in Q1 2021, with the low at $34.0 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $119.0 million, with a median of $125.4 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents plummeted 67.88% in 2023, then skyrocketed 389.54% in 2025.
  • Over 5 years, Cash & Equivalents stood at $149.8 million in 2021, then crashed by 39.61% to $90.5 million in 2022, then tumbled by 52.55% to $42.9 million in 2023, then rose by 20.84% to $51.9 million in 2024, then soared by 256.28% to $184.8 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $184.8 million, $166.4 million, and $137.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.